Clearmind Medicine to issue $2.0 million of convertible promissory notes to CLA Investors under amended SPAs
Clearmind Medicine Inc. announced on October 16, 2026 that it delivered a notice to the CLA Investors to issue and sell convertible promissory notes in an aggregate principal amount of $2,000,000 for an aggregate cash purchase price of $1,800,000 (90% of principal). The issuance is made under the securities purchase agreements dated September 17, 2025, as amended on April 30, 2026, which permit the issuance of convertible promissory notes in an aggregate principal amount of up to $10,000,000. The transaction is...
Key takeaways
Convertible note tranche: $2,000,000 aggregate principal of convertible promissory notes to be sold to the CLA Investors for $1,800,000 cash, equal to 90% of principal.
Facility capacity: issuance is under the September 17, 2025 SPAs as amended on April 30, 2026, permitting up to $10,000,000 of convertible promissory notes in aggregate principal.
Timing: notice delivered October 16, 2026; closing expected on or before October 19, 2026.
Shelf coverage: 6-K is incorporated by reference into five Form F-3 registration statements (File Nos. 333-275991, 333-270859, 333-273293, 333-293521 and 333-295455) and Form S-8 (File No. 333-283695).
Filing form: report furnished as Form 6-K by foreign private issuer Clearmind Medicine Inc. (Commission file number 001-41557) and signed by CEO Adi Zuloff-Shani.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow CMND in real time
Get material earnings, filing, IR, and earnings-call alerts by email.